Starting Cancer Care

Cancer is a group of diseases in which abnormal cells grow without normal control. These cells may invade nearby tissues and, in some cancers, travel to other parts of the body. Cancer is not one single illness: its behaviour and treatment depend on where it started, its microscopic type, its stage, its molecular features and the person's overall health. Many cancers are curable, especially when detected early, while others can be controlled for long periods with modern treatment.

No. A tumour is an abnormal growth, but it may be benign or malignant. Benign tumours do not invade nearby tissues or spread to distant organs, although they can still cause problems because of their size or location. Malignant tumours are cancers and may invade or spread. A scan alone may not reliably distinguish the two; clinical assessment and, when appropriate, a biopsy are used to establish the diagnosis.

A benign tumour generally grows locally and does not metastasise. A malignant tumour can invade surrounding tissue and may spread through lymphatic channels or the bloodstream. Some benign tumours still require treatment if they compress an organ, produce hormones or continue to enlarge. The final classification is usually based on pathology, not simply on symptoms or scan appearance.

Cancer develops after changes accumulate in genes that control cell growth and repair. Tobacco, alcohol, certain infections, ultraviolet or ionising radiation, obesity, ageing, inherited variants and some occupational exposures can increase risk. Often there is no single identifiable cause, and developing cancer is not the patient's fault. Reducing avoidable risks and participating in appropriate screening can lower risk, but cannot prevent every cancer.

Most cancers are not directly inherited. About 5-10% are strongly linked to an inherited harmful genetic variant, while family patterns may also reflect shared environment or several small genetic influences. Features such as cancer at a young age, multiple related cancers in one person, bilateral disease or several affected close relatives may justify genetic counselling. Genetic testing is best chosen after counselling because the correct test and interpretation depend on the family and tumour history.

No. Cancer is not contagious and cannot be transmitted by touching, sharing food, living together or caring for someone. Some infections that increase cancer risk, such as HPV or hepatitis B and C, can be transmitted, but the cancer itself cannot. Family members do not need to isolate from a patient with cancer. Normal supportive contact is safe and valuable.

Stage describes how far a cancer has spread at diagnosis. Depending on the cancer, it may consider the size and local extent of the primary tumour, nearby lymph nodes and distant metastases. Staging systems differ between cancers, so the same stage number does not have the same meaning in every disease. Stage helps guide treatment and discuss prognosis, but it is only one part of an individual patient's outlook.

Stage describes the anatomical extent of cancer in the body. Grade describes how abnormal the cancer cells look under the microscope and may indicate how quickly they are likely to grow. A small tumour can be high grade, and an advanced tumour can sometimes be low grade. Both features, together with biomarkers and the patient's health, help determine treatment.

Metastasis means cancer cells have spread from the organ where the cancer began to another part of the body. The new deposit retains the identity of the original cancer; for example, breast cancer in bone is metastatic breast cancer, not bone cancer. Metastatic disease may be treated with systemic medicines, radiotherapy, surgery or other local procedures depending on the situation. Treatment may control disease, relieve symptoms and sometimes produce long remissions.

No. Stage IV usually means distant spread, but treatment is often possible and worthwhile. The aim may be long-term disease control, symptom relief, preservation of function and extension of life; in selected cancers, cure or exceptionally durable remission may still occur. Expected benefit varies greatly by cancer type, biomarkers, sites of spread and general health. The treatment goal should be discussed openly rather than inferred from the stage number alone.

Yes, recurrence is possible because a very small number of cancer cells may remain undetectable after treatment. Risk varies widely according to cancer type, stage, biology and response to therapy, and many people never experience recurrence. Recommended follow-up aims to manage treatment effects and identify clinically important problems. New persistent symptoms should be reported, but routine anxiety-driven scans are not always beneficial.

Healthy habits reduce risk but cannot eliminate it. Ageing, random errors during cell division, inherited susceptibility, infections and exposures that are not recognised may all contribute. A cancer diagnosis should not be viewed as personal failure or punishment. Healthy eating, physical activity, avoidance of tobacco and appropriate vaccination and screening remain valuable before, during and after treatment.

Diagnosis begins with history and examination, followed by tests chosen for the suspected organ. These may include blood tests, ultrasound, CT, MRI, endoscopy or mammography. In most solid tumours, tissue obtained by biopsy or surgery is required to confirm cancer and its exact type. Pathology, staging and biomarker results are then combined to plan treatment.

A biopsy is required for most suspected cancers before systemic treatment or major cancer surgery because different diseases can look similar on scans. There are limited exceptions where imaging, blood markers and clinical circumstances are sufficiently characteristic, or where biopsy risk outweighs benefit. The safest method may be needle biopsy, endoscopic biopsy, excision or bone marrow sampling. The treating team should explain why a particular approach is recommended.

Routine biopsy does not cause cancer to spread. Biopsy is essential for confirming the diagnosis and selecting appropriate treatment. In a few tumour types, especially suspected bone or soft-tissue sarcoma, the biopsy path must be planned carefully so it can be removed during definitive surgery. Fear of spread should not delay a properly planned, medically recommended biopsy.

Histopathology is examination of tissue by a pathologist using microscopy and, when needed, additional laboratory techniques. It identifies whether cancer is present, the cancer type, grade and other features that affect treatment. The report may be supplemented by immunohistochemistry, molecular tests or expert review. Pathology is a central part of diagnosis and sometimes takes several days because accuracy requires careful processing.

Immunohistochemistry, or IHC, uses antibodies to detect specific proteins in tumour cells. It can help determine where a cancer originated, distinguish between similar-looking diseases and identify treatment-relevant markers such as hormone receptors or HER2. IHC results must be interpreted together with the tissue appearance and clinical findings. One isolated marker rarely provides the entire diagnosis.

Biomarker testing looks for genes, proteins or other features that may clarify prognosis or predict response to a targeted drug, immunotherapy or hormonal treatment. The required tests differ by cancer and stage; not every patient needs a broad gene panel. Testing may use tumour tissue, blood or both. Results should be interpreted by the oncology team because an alteration does not always mean an available drug will be effective.

CT provides detailed cross-sectional anatomy and is widely used for staging and response assessment. MRI is particularly useful for the brain, spine, pelvis, liver and soft tissues, and does not use ionising radiation. PET-CT shows areas of increased metabolic activity and is valuable in selected cancers, but inflammation and infection can also appear active. The best scan depends on the cancer and the clinical question.

No. Infection, inflammation, recent surgery, healing fractures and normal organs can take up the PET tracer. Conversely, some small or slow-growing cancers may show little uptake. PET findings must be interpreted alongside the CT appearance, history and prior imaging. When the result would change treatment, biopsy or interval imaging may be required.

Tumour markers are substances found in blood, urine or tissue that may provide information about a cancer. They can sometimes assist diagnosis, guide treatment, monitor response or raise concern about recurrence. Most are not specific: benign conditions may increase them, and a normal result does not exclude cancer. Trends interpreted in clinical context are often more informative than a single value.

The first report may confirm malignancy but further IHC, cytogenetic or molecular testing may be needed to define the exact subtype and select treatment. Staging scans and organ-function tests answer different questions from the biopsy. Occasionally, the original sample is too small or damaged and a repeat biopsy is needed. A short wait for essential results can prevent the wrong treatment from being started.

Review is particularly valuable when the diagnosis is rare, the report is uncertain, findings do not match the clinical picture, or treatment carries major consequences. It may also be requested at a tertiary centre before surgery or systemic therapy. Most straightforward diagnoses do not require multiple reviews. Slides, blocks and reports should be preserved because they may be needed for review or later biomarker testing.

Bone marrow examination samples the blood-forming tissue, usually from the back of the pelvic bone. Aspiration provides liquid marrow for cell examination, flow cytometry and genetic tests; trephine biopsy provides a small core showing marrow structure. It is mainly used for suspected or known blood disorders and selected staging questions. Local anaesthetic reduces pain, although brief pressure or pulling discomfort may occur.

Bring the biopsy report, pathology slides or blocks if available, scan reports and image discs or online access, operation notes, discharge summaries, previous treatment records and recent blood tests. Also bring a list of medicines, allergies and major illnesses. Arrange records chronologically and retain copies. Incomplete information can delay decisions or lead to unnecessary repetition of tests.

Yes, if you are comfortable with it. A trusted person can listen, take notes, help recall information and support decision-making. The patient should still be addressed directly and decide what information may be shared. If no one can attend, ask whether you may record key instructions or request a written treatment summary.

Ask about the exact diagnosis, stage, treatment goal, available options, expected benefit, important side effects, alternatives, cost and what happens without treatment. Clarify whether more tests are needed, how response will be assessed and which symptoms require urgent care. Ask how treatment may affect work, fertility and other illnesses. Writing down your three most important questions before the visit helps ensure they are addressed.

Yes. A second opinion is reasonable, especially for a rare cancer, major surgery, uncertain pathology or a decision with several valid options. It does not usually offend the treating doctor and may confirm the plan or identify alternatives. Obtain complete records and ask whether any proposed delay is safe. Emergency problems and rapidly progressive disease should not be left untreated while opinions are collected.

The safe interval varies widely. Some aggressive leukaemias, lymphomas and symptomatic cancers require urgent action, whereas many breast, prostate or thyroid cancers allow time for complete staging, biomarker testing and treatment planning. Starting before essential information is available can be harmful. Ask your oncologist for a specific timeframe and which symptoms should trigger earlier review.

The team considers cancer type, stage, grade, biomarkers, symptoms, organ function, age, other illnesses, prior treatments and the patient's priorities. Evidence-based guidelines and multidisciplinary discussion may inform the recommendation. Cost, travel, fertility, caregiving and work constraints also matter. Shared decision-making means understanding the likely benefits and burdens and choosing a medically reasonable option consistent with the patient's goals.

Yes, if they are available. The pathology report is essential, and the oncologist may request the glass slides or paraffin tissue block for review, additional immunohistochemistry or molecular testing. Ask the laboratory how the material should be collected, transported and returned.

Bring both the written reports and the images, preferably on CD, pen drive or the hospital’s online image portal. Images allow the oncologist and radiologist to review tumour location, measurements and surgical or biopsy planning rather than relying only on the report.

Bring pathology reports, scan reports and images, operation notes, discharge summaries, blood-test results, previous treatment details, current prescriptions, allergy information and relevant insurance documents. Arrange them by date and carry a one-page list of diagnoses, medicines and important medical problems.

Usually yes, unless another clinician has specifically asked you to stop. Bring a complete list including insulin, blood thinners, steroids, supplements and herbal products. Never stop anticoagulants, antiepileptics, steroids or heart medicines merely because an oncology appointment is planned.

Usually you may eat normally. Fasting is needed only when a planned blood test, scan, sedation or procedure requires it. If the hospital has scheduled such a test on the same day, follow its written preparation instructions.

A trusted relative or friend can help remember information, take notes and discuss practical support. The patient should still be included directly in decisions and may request private time with the clinician.

For most cancers, a promptly arranged second opinion causes little or no harmful delay and may confirm the diagnosis or options. Some aggressive cancers and urgent complications require rapid treatment, so ask the oncologist how much time is medically safe and send records in advance.

Ask about the exact diagnosis, stage, treatment goal, alternatives, expected benefit, common and serious side effects, fertility implications, cost, duration, monitoring and urgent-contact plan. The checklist at the end of this guide can be printed and taken to the visit.